https://orcid.org/0000-0001-8381-5253
Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
G. Dalla Costa, L. Leocani & G. Comi. (2022) Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology 18:2, pages 105-114.
Read now
Read now
Michael Levy & Maureen A Mealy. (2021) B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20. ImmunoTargets and Therapy 10, pages 325-331.
Read now
Read now
Tereza Gabelić, Barbara Barun, Ivan Adamec, Magdalena Krbot Skorić & Mario Habek. (2021) Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis. Human Vaccines & Immunotherapeutics 17:11, pages 4345-4362.
Read now
Read now
Articles from other publishers (19)
Yılmaz İNANÇ & Selçuk NAZİK. (2023) Status of Hepatitis B Virus Serological In Patients With Multipl Sclerosis Using OcrelizumabOcrelizumab Kullanan Multipl Skleroz Hastalarında Hepatit B Virüsü Serolojisi. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 18:3, pages 51-54.
Crossref
Crossref
Sabine Lieb, Maria Heni, Sophie Rauschenberg, Kay Lange, Juergen Feisthammel, Hendrik Bläker & Johannes Wiegand. (2023) Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis. Zeitschrift für Gastroenterologie 61:11, pages 1500-1503.
Crossref
Crossref
Giuseppina Miele, Gianmarco Abbadessa, Elisabetta Maida & Simona Bonavita. (2023) Viral pericarditis following ocrelizumab in a multiple sclerosis patient. Neurological Sciences 44:8, pages 2947-2949.
Crossref
Crossref
Vasileios-Periklis Stamatellos & Georgios Papazisis. (2023) Safety and Monitoring of the Treatment with Disease-Modifying Therapies
(DMTs) for Multiple Sclerosis (MS). Current Reviews in Clinical and Experimental Pharmacology 18:1, pages 39-50.
Crossref
Crossref
Aysan Moeinafshar & Nima Rezaei. 2023. Translational Neuroimmunology, Volume 8. Translational Neuroimmunology, Volume 8
191
207
.
Simon Faissner & Ralf Gold. (2022) Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments. CNS Drugs 36:8, pages 803-817.
Crossref
Crossref
Mengbing Lin, Jian Zhang, Yueling Zhang, Jiefeng Luo & Shengliang Shi. (2022) Ocrelizumab for multiple sclerosis. Cochrane Database of Systematic Reviews 2022:5.
Crossref
Crossref
Nik Krajnc, Gabriel Bsteh, Thomas Berger, Jan Mares & Hans-Peter Hartung. (2022) Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 19:3, pages 753-773.
Crossref
Crossref
Ide Smets & Gavin Giovannoni. (2022) Derisking CD20-therapies for long-term use. Multiple Sclerosis and Related Disorders 57, pages 103418.
Crossref
Crossref
Malgorzata Mikulska & Diana Averbuch. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
113
151
.
Kenji Kufukihara. (2021) Anti‐B cell therapies in multiple sclerosis. Clinical and Experimental Neuroimmunology 12:4, pages 228-237.
Crossref
Crossref
Serena Brancati, Lucia Gozzo, Laura Longo, Daniela Cristina Vitale & Filippo Drago. (2021) Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?. Frontiers in Immunology 12.
Crossref
Crossref
N.R. Oksbjerg, S.D. Nielsen, M. Blinkenberg, M. Magyari & F. Sellebjerg. (2021) Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Multiple Sclerosis and Related Disorders 52, pages 102988.
Crossref
Crossref
Hans-Peter Hartung, Jan Mares, Sven G. Meuth & Thomas Berger. (2021) Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. Neurotherapeutics 18:3, pages 1654-1656.
Crossref
Crossref
Finn Sellebjerg & Martin S. Weber. (2021) Targeting B cells in multiple sclerosis. Current Opinion in Neurology 34:3, pages 295-302.
Crossref
Crossref
Andrew R. Romeo. (2021) Recent advances in the treatment of neuromyelitis optica spectrum disorders. Current Opinion in Rheumatology 33:3, pages 233-239.
Crossref
Crossref
Aurora Zanghì, Antonio Gallo, Carlo Avolio, Rocco Capuano, Matteo Lucchini, Maria Petracca, Simona Bonavita, Roberta Lanzillo, Diana Ferraro, Erica Curti, Maria Buccafusca, Graziella Callari, Stefania Barone, Giuseppe Pontillo, Gianmarco Abbadessa, Valeria Di Francescantonio, Elisabetta Signoriello, Giacomo Lus, Patrizia Sola, Franco Granella, Paola Valentino, Massimiliano Mirabella, Francesco Patti & Emanuele D’Amico. (2021) Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics 18:2, pages 1166-1174.
Crossref
Crossref
Johann Sellner & Paulus S. Rommer. (2021) Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines 9:2, pages 99.
Crossref
Crossref
Jonas Graf, Jan MaresMichael BarnettOrhan Aktas, Philipp Albrecht, Scott S. ZamvilHans-Peter Hartung. (2021) Targeting B cells to modify MS, NMOSD, and MOGAD. Neurology Neuroimmunology & Neuroinflammation 8:1.
Crossref
Crossref